Document is current
Any future updates will be listed below
-
Authors
Mardinoglu, Adil https://orcid.org/0000-0002-4254-6090
Turkez, Hasan
Shong, Minho https://orcid.org/0000-0002-0247-7115
Srinivasulu, Vishnuvardhan Pogunulu https://orcid.org/0009-0002-9859-3838
Nielsen, Jens https://orcid.org/0000-0002-9955-6003
Palsson, Bernhard O https://orcid.org/0000-0003-2357-6785
Hood, Leroy https://orcid.org/0000-0001-7158-3678
Uhlen, Mathias https://orcid.org/0000-0002-4858-8056
-
Funding
Funding for this research was provided by:
Knut och Alice Wallenbergs Stiftelse (72254)
National Research Foundation of Korea (NRF-2023-R1A2C3003438)
- License Information
-
More Information
Article History
Received: 21 March 2025
Revised: 30 June 2025
Accepted: 2 July 2025
First Online: 5 August 2025
Disclosure and competing interests statement
: AM co-founded SZA Longevity, Trustlife Therapeutics, ScandiBio Therapeutics and ScandiEdge Therapeutics; MS co-founded SILK Longevity; VPS co-founded Vizzhy Longevity; LH co-founded Phenome Health; BOP co-founded Pasteur 21, Sinopia Biosciences and Conarium Bioworks; and MU co-founded ScandiBio Therapeutics, ScandiEdge Therapeutics and ProteomEdge.
